Radiolabeled Monoclonal Antibody in Treating Patients With Glioblastoma Multiforme or Anaplastic Astrocytoma

You may be eligible if

• DISEASE CHARACTERISTICS:
• Histologically confirmed newly diagnosed unresectable glioblastoma multiforme (GBM), recurrent GBM, or recurrent anaplastic astrocytoma (AA)
• MRI scan documenting gadolinium enhanced tumor volume of at least 5 cm3, but no greater than 60 cm\^3
• * Recurrent GBM and AA must be documented by MRI after the most recent treatment and before any planned surgical debulking
• At least 5 days since prior surgical debulking
• No planned resection of newly diagnosed GBM before or during study
• No bilateral noncontiguous gadolinium enhancing tumors
• No satellite lesions greater than 1.5 cm from anticipated location of interstitial catheter tip
• No more than 2 satellite lesions
• PATIENT CHARACTERISTICS:
• Age:
• 18 and over
• Performance status:
• Karnofsky 60-100%
• Life expectancy:
• Not specified
• Hematopoietic:
• Platelet count at least 100,000/mm\^3
• Absolute neutrophil count at least 1,500/mm\^3
• WBC at least 3,000/mm\^3
• Hepatic:
• Hepatitis B surface antigen negative
• Bilirubin no greater than 2.5 times upper limit of normal (ULN)
• SGOT and SGPT no greater than 3 times ULN
• Alkaline phosphatase no greater than 3 times ULN
• Lactic dehydrogenase no greater than 3 times ULN
• Prothrombin time no greater than 1.5 times ULN
• Renal:
• Creatinine clearance at least 50 mL/min
• Cardiovascular:
• No significant unstable cardiovascular disease
• No New York Heart Association class III/IV heart disease
• No evidence of myocardial infarction within the past 3 months
• Other:
• Not pregnant
• Negative pregnancy test
• Fertile patients must use effective contraception
• Human antichimeric antibody (HACA) titer no greater than 48 ng/mL
• No anatomical or physiological considerations that would preclude study participation
• No active autoimmune disease, active infection, or traumatic injury requiring treatment
• HIV negative
• PRIOR CONCURRENT THERAPY:
• Biologic therapy:
• Not specified
• Chemotherapy:
• At least 4 weeks since prior intravenous chemotherapy or Gliadel wafers
• Endocrine therapy:
• Not specified
• Radiotherapy:
• At least 8 weeks since prior external beam or gamma knife radiotherapy
• Surgery:
• See Disease Characteristics
• Other:
• At least 30 days since prior investigational treatment